Post
Happy_shanky
đš $LLY â ELI LILLYâS NEXT OBESITY DRUG SHOWS STRONG RESULTS
ELI LILLYâS EXPERIMENTAL ELORALINTIDE, WHEN COMBINED WITH ZEPBOUND, PRODUCED AN AVERAGE 23.3% WEIGHT LOSS OVER AROUND 11 MONTHS.
THAT COMPARES WITH 14.8% FOR ZEPBOUND ALONE IN PATIENTS WITH TYPE 2 DIABETES.
â ïž HOWEVER, 11%â27% OF PATIENTS STOPPED THE COMBINATION DUE TO SIDE EFFECTS, KEEPING TOLERABILITY AS AN IMPORTANT CONSIDERATION.
LILLY EXPECTS TO MOVE ELORALINTIDE INTO LATE-STAGE TRIALS LATER THIS YEAR.
#DailyOrbit
Ansvarsfriskrivning: OKX Orbit-innehÄll tillhandahÄlls endast i informationssyfte. LÀs mer
Svar
Inga kommentarer Àn. Var den första att svara!
Dagens marknadsrykte
1#USNFPDataCools
PopulÀrt
2#BTCETHETFOutflows
3#G7OilReserveRelease
